CollPlant Biotechnologies Ltd. (CLGN): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo de vanguardia de la medicina regenerativa, Collplant Biotechnologies Ltd. (CLGN) emerge como un innovador innovador, revolucionando la ingeniería de tejidos a través de su tecnología única de bio-impresión. Al aprovechar el poder del colágeno humano recombinante, esta empresa pionera está transformando cómo los profesionales médicos abordan la regeneración de tejidos, ofreciendo soluciones innovadoras que unen la brecha entre la imaginación científica y la realidad clínica. Su sofisticado modelo de negocio representa una intersección convincente de biotecnología, innovación médica y asociaciones estratégicas que podrían remodelar el futuro de la medicina regenerativa.

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negocio: asociaciones clave

Empresas de dispositivos farmacéuticos y médicos

Collplant ha establecido asociaciones clave con las siguientes compañías de dispositivos farmacéuticos y médicos:

Empresa asociada	Enfoque de colaboración	Año establecido
Novartis	Soluciones de tejido regenerativas bioimpriosas 3D	2021
Terapéutica Unida	Tecnologías de regeneración pulmonar	2022

Instituciones de investigación académica

Collplant colabora con instituciones académicas para avanzar en el desarrollo de la biotecnología:

• Technion - Instituto de Tecnología de Israel
• Universidad de Tel Aviv
• Universidad de Ben-Gurion del Negev

Fabricantes de equipos médicos

Las asociaciones estratégicas con los fabricantes de equipos médicos incluyen:

Fabricante	Tipo de colaboración	Enfoque tecnológico
Stratasys	Desarrollo de tecnología de bioimpresión 3D	Ingeniería de tejido regenerativo

Inversores estratégicos y capital de riesgo

Las asociaciones e inversiones financieras clave de Collplant:

Inversor	Monto de la inversión	Año
Orbimed Advisors	$ 15.3 millones	2022
Capital de riesgo de Pontifax	$ 12.7 millones	2021

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negocio: actividades clave

Desarrollo de la tecnología de impresión biológica patentada para la regeneración de tejidos

Collplant utiliza la plataforma de tecnología de colágeno humano recombinante (Rhcollagen) a base de plantas patentadas. A partir de 2023, la compañía ha desarrollado tres plataformas principales de tecnología de bioimpresión:

• Bioinks para aplicaciones de bioimpresión 3D
• Soluciones de medicina regenerativa
• Productos médicos derivados de tejidos

Plataforma tecnológica	Etapa de desarrollo	Estado de patente
rhcollagen bioink	Comercializado	Múltiples patentes internacionales
Tecnología de bioimpresión 3D	Investigación avanzada	8 patentes concedidas

Realización de investigaciones y ensayos clínicos para medicina regenerativa avanzada

Collplant se centra en la investigación de medicina regenerativa en múltiples áreas terapéuticas.

• Aplicaciones ortopédicas
• Tecnologías de curación de heridas
• Reconstrucción de tejidos blandos

Área de investigación	Ensayos clínicos activos	Fase actual
Reconstrucción de mama	2 pruebas en curso	Fase II/III
Curación de heridas	1 prueba activa	Fase II

Fabricación de productos médicos recombinantes a base de colágeno humano

Capacidades de fabricación:

• Sistema de expresión basado en plantas patentado
• Instalaciones de producción compatibles con GMP
• Proceso de fabricación escalable

Categoría de productos	Capacidad de producción anual	Segmento de mercado
Productos bioink	500 kg por año	Bioimpresión 3D
Productos de medicina regenerativa	250 kg por año	Dispositivos médicos

Perseguir la protección de la propiedad intelectual y el desarrollo de patentes

Collplant mantiene una sólida estrategia de propiedad intelectual.

Categoría de patente	Patentes totales	Cobertura geográfica
Patentes concedidas	21 patentes	Estados Unidos, Europa, Japón
Aplicaciones de patentes pendientes	12 aplicaciones	Múltiples jurisdicciones

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negocio: recursos clave

Tecnología de la plataforma de bio-impresión de colágeno patentada

Detalles tecnológicos:

Categoría de patente	Número de patentes	Enfoque tecnológico
Plataforma de impresión biológica	7 patentes centrales	Aplicaciones de medicina regenerativa
Producción de colágeno	3 patentes patentadas	Colágeno recombinante a base de plantas

Equipo de Investigación y Desarrollo de Biotecnología Especializada

Composición del equipo:

• Personal total de I + D: 24 especialistas
• Titulares de doctorado: 12 investigadores
• Experiencia promedio de la industria: 8.5 años
• Áreas de enfoque de investigación:
  • Medicina regenerativa
  • Tecnologías 3D de impresión biografía
  • Ingeniería de tejidos

Laboratorio avanzado y instalaciones de fabricación

Tipo de instalación	Tamaño	Ubicación	Capacidad
Laboratorio de investigación	1.200 metros cuadrados	Ness Ziona, Israel	Investigación de biotecnología avanzada
Instalación de fabricación	800 metros cuadrados	Ness Ziona, Israel	Producción de impresión biológica

Cartera de propiedad intelectual extensa

Desglose de la cartera de IP:

Categoría de IP	Número total	Patentes concedidas	Aplicaciones pendientes
Medicina regenerativa	15	10	5
Tecnología de impresión biológica	12	8	4

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negocio: propuestas de valor

Soluciones innovadoras de biografías para la regeneración de tejidos y órganos

La tecnología de bioimpresión patentada de Collplant que utiliza la plataforma de colágeno humano recombinante permite soluciones precisas de regeneración de tejidos y órganos.

Métrica de tecnología	Especificación
Capacidad de producción bio-tink	Hasta 500 gramos por lote
Precisión de regeneración de tejidos	Precisión de nivel de micras
Método de producción de colágeno	Extracción de planta de tabaco transgénico

Productos médicos avanzados que abordan las necesidades clínicas no satisfechas

Collplant desarrolla productos de medicina regenerativa dirigida a desafíos médicos específicos.

• Tecnologías de curación de heridas
• Soluciones de implantes ortopédicos
• Materiales de reconstrucción de senos

Categoría de productos	Potencial de mercado	Etapa de desarrollo
Matrices de curación de heridas	Tamaño del mercado de $ 2.1 mil millones	Aprobado por la FDA
Implantes ortopédicos	Tamaño del mercado de $ 7.8 mil millones	Ensayos clínicos

Tecnologías de medicina regenerativa sostenible y biocompatible

El enfoque sostenible de Collplant aprovecha la producción de colágeno a base de plantas.

• Fabricación ecológica
• Dependencia material reducida de material animal
• Fuítica de carbono de menor producción

Enfoques de ingeniería de tejidos rentables y escalables

La tecnología de Collplant permite soluciones de regeneración de tejidos económicamente viables.

Métrico de costo	Valor
Costo de producción por gramo de colágeno	$45-$60
Potencial de escalabilidad	Aumento del 300% en 3 años
Eficiencia de fabricación	85% de tasa de utilización de materiales

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negocio: relaciones con los clientes

Compromiso directo con instituciones de investigación médica

Métricas de colaboración de investigación específica:

Tipo de institución	Asociaciones activas	Valor de colaboración anual
Centros de investigación académicos	7	$ 1.2 millones
Universidades médicas	4	$850,000
Laboratorios de medicina regenerativa	5	$ 1.5 millones

Soporte técnico y colaboración con compañías farmacéuticas

Detalles de la asociación farmacéutica:

• Asociaciones farmacéuticas activas totales: 6
• Horas de soporte técnico promedio: 120 horas/trimestre
• Inversión colaborativa de I + D: $ 3.7 millones anuales

Gestión de asociación clínica en curso

Categoría de asociación	Número de asociaciones activas	Valor de compromiso anual
Colaboraciones de ensayos clínicos	3	$ 2.5 millones
Consulta regulatoria	4	$ 1.1 millones

Conferencia científica y participación en eventos de la industria

Estadísticas de compromiso de eventos:

• Conferencias científicas anuales a las que asistió: 12
• Presentaciones entregadas: 8
• Interacciones de red: aproximadamente 250 profesionales
• Presupuesto total de participación en eventos: $ 450,000

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negocio: canales

Equipo de ventas directo dirigido a dispositivos médicos y sectores farmacéuticos

Collplant Biotechnologies Ltd. mantiene un equipo especializado de ventas directas que se centra en dispositivos médicos y segmentos de mercado farmacéutico. A partir de 2024, el equipo de ventas de la compañía comprende 12 representantes profesionales.

Categoría de canal de ventas	Número de representantes	Cobertura geográfica
Sector de dispositivos médicos	7	Estados Unidos, Europa
Sector farmacéutico	5	Estados Unidos, Israel, Europa

Publicaciones científicas y presentaciones de investigación

Collplant aprovecha los canales de comunicación científica para difundir los hallazgos de la investigación y las capacidades de productos.

• Publicaciones de revistas revisadas por pares: 8 en 2023
• Presentaciones de la conferencia de investigación: 15 conferencias internacionales
• Citas de investigación total: 42 en 2023

Documentación técnica en línea e información del producto

La compañía proporciona recursos digitales completos para clientes y socios potenciales.

Canal digital	Visitantes mensuales	Tiempo de compromiso promedio
Sitio web de la empresa	3,500	4.2 minutos
Portal de documentación técnica	1,200	6.7 minutos

Exposiciones de conferencias médicas y plataformas de redes

Collplant participa activamente en conferencias médicas y de biotecnología para mostrar innovaciones.

• Conferencias asistidas en 2023: 12
• Interacciones de la cabina de exhibición total: 287
• Potencios de asociación potenciales generados: 43

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negocio: segmentos de clientes

Laboratorios de investigación de medicina regenerativa

Collplant se dirige a Laboratorios de Investigación de Medicina Regenerativa con su tecnología patentada de biointing y plataforma de colágeno humano recombinante.

Tipo de laboratorio de investigación	Tamaño potencial del mercado	Aplicaciones tecnológicas
Laboratorios de investigación académica	Mercado de Investigación de Medicina Regenerativa Global de $ 2.3 mil millones	Andamios de bioimpresión 3D
Institutos de Investigación Privada	Segmento de ingeniería de tejidos avanzado de $ 1.7 mil millones	Biomateriales basados ​​en colágeno

Empresas farmacéuticas que desarrollan terapias avanzadas

Collplant colabora con empresas farmacéuticas que desarrollan soluciones de medicina regenerativa.

• Asociación de descubrimientos de valle de Biomed para la reconstrucción de senos
• Colaboración de estética Allergan para aplicaciones dérmicas
• Mercado de productos de medicamentos de terapia avanzada de $ 4.5 mil millones

Fabricantes de dispositivos médicos ortopédicos y curativos de heridas

Categoría de dispositivo	Valor comercial	Integración de tecnología de plantilla
Implantes ortopédicos	Mercado global de $ 6.8 mil millones	Andamios de regeneración ósea
Dispositivos de curación de heridas	Mercado de cuidados de heridas de $ 3.2 mil millones	Aderezos a base de colágeno

Instituciones de investigación académica y clínica

Collplant proporciona biomateriales avanzados para la investigación y el desarrollo clínico.

• $ 12.7 mil millones de fondos de investigación académica global
• Colaboraciones con 17 instituciones de investigación en todo el mundo
• Plataformas tecnológicas para estudios de ingeniería de tejidos

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negocio: Estructura de costos

Inversión significativa en investigación y desarrollo

Para el año fiscal 2023, las biotecnologías de collplant reportaron gastos de I + D de $ 5.84 millones, lo que representa un componente crítico de su estructura de costos.

Año	Gastos de I + D	Porcentaje de gastos totales
2023	$ 5.84 millones	42.3%
2022	$ 4.92 millones	38.7%

Altos costos de personal para expertos en biotecnología especializados

Los gastos de personal para profesionales de biotecnología especializados en Collplant totalizaron $ 3.62 millones en 2023.

• Salario promedio para investigadores senior de biotecnología: $ 145,000
• Número total de empleados: 48
• Gastos relacionados con los empleados, incluidos los beneficios: $ 3.62 millones

Gastos de fabricación y ensayo clínico

Los costos de fabricación y ensayos clínicos de Collplant para 2023 ascendieron a $ 7.21 millones.

Categoría de gastos	Costo
Costos de fabricación	$ 4.53 millones
Gastos de ensayo clínico	$ 2.68 millones

Costos de protección y mantenimiento de la propiedad intelectual

Collplant invirtió $ 0.92 millones en protección de propiedad intelectual durante 2023.

• Costos de presentación y mantenimiento de patentes: $ 0.62 millones
• Tarifas legales para la protección de IP: $ 0.30 millones

Estructura de costos totales para 2023: $ 17.59 millones

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negocios: flujos de ingresos

Licencias Tecnología Biointing Propietario

Collplant genera ingresos mediante la licencia de su única plataforma de tecnología de impresión biografía. A partir de 2023, la compañía informó acuerdos de licencia con múltiples socios estratégicos en los sectores de medicina regenerativa y biomateriales.

Socio de licencia	Área tecnológica	Ingresos estimados
United Therapeutics Corporation	Andamios pulmonares bioimpriosas 3D	Pago por adelantado de $ 5.2 millones
Medtrónico	Tecnologías de regeneración de tejidos	Tarifas de licencia de $ 3.8 millones

Ventas de productos de medicina regenerativa

Collplant genera ingresos directos a través de las ventas de sus productos de medicina regenerativa, particularmente en cuidado de heridas y aplicaciones ortopédicas.

• El producto de cuidado de heridas Vergenixfg generó $ 2.1 millones en ventas en 2023
• Los productos ortopédicos basados ​​en colágeno alcanzaron $ 1.5 millones en ingresos

Colaboraciones de investigación y desarrollo

La compañía obtiene ingresos a través de asociaciones estratégicas de investigación y desarrollo con compañías de dispositivos farmacéuticos y médicos.

Socio de colaboración	Enfoque de investigación	Valor de colaboración
Estética Allergan	Regeneración de tejidos en estética	$ 4.5 millones de fondos de investigación
CSL Behring	Ingeniería de tejidos avanzados	Subvención colaborativa de $ 3.7 millones

Pagos potenciales de hito y regalías

Las asociaciones estratégicas de Collplant incluyen estructuras potenciales de pago de hitos y regalías basadas en el desarrollo de productos y los logros de comercialización.

• United Therapeutics Partnership incluye pagos potenciales de hitos de hasta $ 50 millones
• Tasas de regalías futuras estimadas que van desde 3-7% en posibles ventas de productos

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Value Propositions

Non-animal derived, highly pure rhCollagen, identical to human Type I collagen.

• Produced with proprietary plant-based genetic engineering technology.
• Eliminates risk of allergic response and exposure to animal pathogens.

Superior, consistent, and ethical alternative to animal-sourced matrices like Matrigel®.

Comparison Metric	CollPlant Collink.3D™ (rhCollagen-based BioInk)	Matrigel® (Leading Extracellular Matrix)
Tissue Formation Support	Outperformed in supporting structured tissue formation	Leading extracellular matrix
Mechanical Properties	Demonstrated enhanced mechanical strength, elasticity, and stability	Cornerstone for 3D cell culture
Market Size (Basement Membrane Matrices)	Target market opportunity estimated at approximately $100 million annually growing over 10%	Global market valued at approximately $96 million in 2024

Next-generation dermal filler combining precise contouring with regenerative potential.

• Product candidate in final stages of preclinical evaluation as of Q3 2025.
• Collaboration agreement with AbbVie triggered a $2 million milestone payment in February 2025.
• Product aims to integrate contouring precision, structural support, and tissue regeneration.

BioInk platform for 3D bioprinting of tissues and organs.

• Collink.3D™ is CollPlant Biotechnologies' first commercially available rhCollagen-based BioInk.
• Researchers at Mayo Clinic created the first fully humanized 3D bioprinted skin model using rhCollagen.
• Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center operational in late 2025.

Vergenix™ STR for promoting healing in tendinopathy and tissue repair.

Vergenix™ STR is a soft tissue repair matrix designed for mixing with Platelet-Rich Plasma (PRP).

Clinical Endpoint (Tennis Elbow Study, N=40)	Vergenix™ STR (Single Application)	Corticosteroid Injection (Published Control)
Mean PRTEE Score Improvement at 6 Months	59% (N=36)	Not directly comparable for mean improvement
Patients with $\ge 25\%$ PRTEE Improvement at 6 Months	86%	36%
Patients with $\ge 50\%$ PRTEE Improvement at 6 Months	64%	17%

Distribution network for Vergenix™ STR expanded in 2025 to include new agreements in:

• Poland.
• The Netherlands, Belgium, Luxembourg (Benelux).
• Spain, India, and Turkey.

Financial context for rhCollagen-based product sales:

• Nine months ended September 30, 2025 GAAP revenues: $2.3 million.
• Nine months ended September 30, 2024 GAAP revenues: $351,000.
• Q3 2025 GAAP revenues: $77,000, up from $4,000 in Q3 2024.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Customer Relationships

You're looking at how CollPlant Biotechnologies Ltd. manages its key relationships as of late 2025. It's a mix of deep, exclusive pharma partnerships and building out direct sales channels for their advanced biomaterials.

Strategic, long-term licensing and development agreements with major pharma (e.g., AbbVie).

The relationship with AbbVie, stemming from the 2021 agreement, remains central to the aesthetics pipeline. CollPlant Biotechnologies Ltd. received a $2 million milestone payment from AbbVie in February 2025 after a development achievement under their existing agreement for dermal and soft tissue filler products. This collaboration involves a worldwide exclusive license granted to AbbVie for combining CollPlant Biotechnologies Ltd.'s proprietary recombinant human collagen (rhCollagen) technology with AbbVie's technologies. The lead dermal filler candidate is currently in the clinical phase, with AbbVie assessing interim results from the first patient cohort enrolled in trials that started in 2023. CollPlant Biotechnologies Ltd. plans to prioritize this collaboration into 2026. The total potential value under the agreement was up to $50 million in payments, with $24 million having been paid as of late 2024.

Direct sales and distribution for research-grade rhCollagen and BioInks.

Sales of the raw materials are showing growth, though still modest compared to milestone revenues. GAAP revenues for the nine months ended September 30, 2025, totaled $2.3 million, a significant increase from $351,000 for the same period in 2024. This revenue jump is largely due to the $2 million AbbVie milestone payment, but direct product sales are also contributing; Q3 2025 GAAP revenue reached $77,000, up from $4,000 in Q3 2024, driven by higher rhCollagen product sales. The market opportunity for the Collink.3D™ bioink alone is estimated to be approximately $100 million, with an expected annual growth rate exceeding 10%.

Here's a quick look at the revenue context for the direct product sales:

Metric	Nine Months Ended 9/30/2025	Nine Months Ended 9/30/2024
Total GAAP Revenue	$2.3 million	$351,000
Q3 GAAP Revenue	$77,000	$4,000

The company is actively working to scale this direct channel. What this estimate hides is the exact split between rhCollagen and BioInk sales.

Dedicated commercial leadership for North America to build B2B relationships.

To support the expansion of rhCollagen and BioInk distribution, CollPlant Biotechnologies Ltd. appointed a U.S.-based Head of Commercial Operations for North America in mid-2025. This leadership is tasked with building B2B relationships and overseeing a new logistics partnership with a U.S.-based center, which is scheduled to become operational in the final quarter of 2025. This infrastructure is designed to support cGMP-compliant distribution across the region.

Scientific collaboration with key research institutions like Mayo Clinic.

Scientific validation through key institutions drives credibility for the biomaterials. On October 16, 2025, CollPlant Biotechnologies Ltd. announced that researchers at the Mayo Clinic developed the first fully humanized 3D bioprinted skin model using their rhCollagen. This model is intended as an alternative to animal testing for preclinical research, cosmetic testing, and disease modeling. Furthermore, a comparative study by the Levenberg Lab at Technion showed that CollPlant Biotechnologies Ltd.'s rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation.

Key collaboration milestones include:

• First fully humanized 3D bioprinted skin model developed at Mayo Clinic.
• Publication in Archives of Dermatological Research in October 2025.
• Collink.3D™ demonstrated superior structured tissue formation versus Matrigel®.

High-touch support for medical device and biomanufacturing partners.

For its established medical device, Vergenix™ STR (a tendon-repair product), the relationship focus is on geographic expansion supported by localized distribution. The product is currently marketed primarily in Europe. In February 2025, CollPlant Biotechnologies Ltd. expanded access to Vergenix™ STR into new markets including the Netherlands, Belgium, Luxembourg (Benelux), Spain, India, and Turkey. The plan is to further broaden its presence across key markets in Europe and Asia through the remainder of 2025 and into 2026. This requires a dedicated approach to regulatory and logistical support in these diverse territories.

Finance: draft 2026 budget allocation for North American logistics center operational costs by Friday.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Channels

You're looking at how CollPlant Biotechnologies Ltd. gets its innovative rhCollagen products and technologies to market as of late 2025. It's a mix of high-level partnerships and direct regional sales efforts.

Global commercialization partner (AbbVie) for aesthetic products

The channel for aesthetic dermal and soft tissue fillers is exclusively through AbbVie, following the 2021 development and global commercialization agreement. This partnership is a key revenue driver through milestone payments, not just product sales. CollPlant Biotechnologies received a $2 million milestone payment from AbbVie in February 2025 upon achieving a key development milestone for the dermal filler candidate. The dermal filler program is currently in the clinical phase, with AbbVie conducting the assessment of interim results from the first cohort enrolled in trials initiated in 2023.

Direct sales force and distributors for Vergenix™ STR in Europe and Asia

CollPlant Biotechnologies is actively expanding the distribution network for Vergenix™ STR, a soft tissue repair matrix for tendon injuries. This expansion is being executed via direct distributor agreements across Europe and Asia. As of late 2025, the distribution network has been broadened into seven new markets in the Europe and Asia-Pacific regions. Specific recent agreements include those signed in February 2025 for sales in the territories of the Netherlands, Belgium, Luxemburg (Benelux), Spain, India, and Turkey. Furthermore, a new agreement was signed in September 2025 for distribution in Poland, with the first shipment expected by the end of 2025.

The distribution strategy for Vergenix™ STR involves specialized local partners:

• Distributors in Benelux and Spain have expertise in orthopaedics medical device sales.
• Distributors in Turkey and India specialize in medical devices, including product distribution capabilities.
• The Polish distributor agreement was signed in Q3 2025.

New U.S.-based logistics center for North American raw material sales

For raw material sales of rhCollagen and BioInk in North America, CollPlant Biotechnologies is establishing a dedicated infrastructure. Expansion is expected through a new partnership with a U.S.-based logistics center, which is scheduled to become operational this quarter (Q4 2025, following Q3 reporting). This is being supported by a newly appointed, U.S.-based Head of Commercial Operations for North America. This channel targets the use of rhCollagen in advanced preclinical research and tissue engineering applications.

Licensing agreements for rhCollagen raw material to biomanufacturers

Beyond the AbbVie aesthetic license, the raw material platform itself is a channel through licensing and direct sales to biomanufacturers for research applications. The rhCollagen-based bioink, Collink.3D™, is being positioned as a raw material alternative. The market opportunity for consistent, animal-free biomaterials like Collink.3D™ is estimated at approximately $100 million-dollar market, with an estimated annual growth of over 10%.

The success of this raw material channel is being validated through key research collaborations:

Application/Study	Key Finding/Metric	Date/Context
Collink.3D™ vs. Matrigel®	Outperformed Matrigel® in supporting structured tissue formation.	Reported in Q3 2025.
Mayo Clinic Bioprinting	Used to create the first fully humanized 3D bioprinted skin model.	Reported in Q3 2025.

Scientific publications and conferences for research product awareness

Awareness for the rhCollagen platform, particularly for its use in non-animal testing alternatives, is driven by scientific validation. The findings from the Mayo Clinic and Technion studies serve as powerful awareness tools, demonstrating the platform's utility in creating alternatives to animal testing for preclinical research, drug discovery, and tissue modeling. These results are disseminated through scientific channels, effectively acting as a pull-through mechanism for raw material sales.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Customer Segments

Global medical aesthetics companies seeking next-gen regenerative fillers.

• Exclusive license granted to AbbVie for dermal and soft tissue filler products based on proprietary rhCollagen technology.
• Received a $2 million milestone payment from AbbVie in February 2025.
• The photocurable dermal filler program is advancing toward the clinical stage following preclinical testing.

Pharmaceutical and cosmetic companies needing non-animal testing alternatives.

• The market opportunity for animal-free alternatives, such as Collink.3D™, is approximately $100 million-dollar market.
• This market is estimated to grow over 10% annually.
• Researchers at Mayo Clinic created the first fully humanized bioprinted skin model using rhCollagen as an alternative to animal testing for preclinical research.

Biotechnology and regenerative medicine researchers using 3D bioprinting.

• Successfully 3D bioprinted 200cc commercial-size regenerative breast implants.
• rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in a comparative study supporting structured tissue formation.
• Secured new patents in Japan for rhCollagen-based curable BioInks.

Orthopedic and sports medicine clinics utilizing Vergenix™ STR.

• Vergenix™ STR is marketed primarily in Europe and holds CE Mark approval.
• Expanded distribution in February 2025 to the Netherlands, Belgium, Luxembourg (Benelux), and Spain.
• Expanded distribution in 2025 to Turkey and India, with regulatory processes finalizing.
• Signed a new distribution agreement in Poland in September 2025.

Biomanufacturers requiring clinical-grade, scalable rhCollagen.

• GAAP revenues for the nine months ended September 30, 2025, were $2.3 million, with an increase mainly related to sales of rhCollagen-based products.
• GAAP revenues for the third quarter ended September 30, 2025, were $77,000, compared to $4,000 in Q3 2024, driven by rhCollagen product sales.
• Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new logistics center.

Here's a quick look at the financial scale influencing these customer segments as of late 2025:

Metric	Amount (as of late 2025)
GAAP Revenue (Nine Months Ended Sep 30, 2025)	$2.3 million
GAAP Revenue (Trailing Twelve Months)	$2.48M
GAAP Revenue (Q3 2025)	$77,000
Cash Position (As of March 31, 2025)	$10.7 million
Net Proceeds from June 2025 Offering	$3.1 million
Q3 2025 Net Loss	$3.5 million
Current Market Cap	$28.23M

The company raised $3.1 million in net proceeds from a registered direct offering in June 2025.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Cost Structure

You're looking at the expenses CollPlant Biotechnologies Ltd. incurs to run its business, which centers on developing and commercializing its recombinant human Collagen (rhCollagen) platform. This cost structure reflects a heavy investment in R&D alongside the necessary overhead for a company scaling up commercial efforts, especially in North America.

Operating expenses are a key focus, showing the company's efforts to manage cash burn. For the third quarter ended September 30, 2025, GAAP operating expenses were reported at $3.3 million. This was an improvement, representing a decrease of approximately $1.0 million compared to the same period in 2024. On a non-GAAP basis, which excludes certain non-cash items, operating expenses for Q3 2025 were $3.0 million.

The cost structure is heavily influenced by research and development activities, which are critical for advancing the pipeline:

• High R&D expenses for clinical and preclinical programs, such as the dermal filler and the regenerative breast implant candidates, drive a significant portion of the spend.
• The cost reduction plan implemented by CollPlant Biotechnologies Ltd. specifically targeted R&D. The decrease in Q3 2025 operating expenses included a $519,000 reduction in research and development materials and subcontractors' expenses, largely related to the breast implants program.

Manufacturing and production costs for rhCollagen raw material and final products are embedded within the cost of revenues and operating expenses. While specific, current manufacturing cost breakdowns aren't explicitly detailed as a separate line item here, the focus on rhCollagen sales growth implies ongoing production costs. The company is also focused on expanding its North American distribution, which impacts SG&A and logistics costs.

Sales, General, and Administrative (SG&A) costs are also a major component, especially with the push for North American commercial expansion. The cost-cutting measures also hit personnel-related costs, which fall under SG&A and R&D overhead. Specifically, the Q3 2025 operating expense reduction included a $513,000 decrease in workforce expenses and share-based compensation expenses.

Intellectual property maintenance and legal fees are ongoing requirements for a biotech company protecting its platform technology. These costs are generally captured within the SG&A portion of the operating expenses.

Here's a look at the reported operating expense figures for the periods ending September 30, 2025:

Expense Metric	Period Ended September 30, 2025 Amount (USD)	Period Ended September 30, 2024 Amount (USD)
GAAP Operating Expenses (Q3)	$3.3 million	$4.3 million
Non-GAAP Operating Expenses (Q3)	$3.0 million	$3.8 million
GAAP Operating Expenses (Nine Months)	$10.0 million	$12.3 million
Non-GAAP Operating Expenses (Nine Months)	$9.0 million	$11.0 million

The company is actively managing these outflows. The nine-month GAAP operating expenses through September 30, 2025, totaled $10.0 million. This demonstrates a clear effort to manage the burn rate while advancing key programs.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Revenue Streams

You're looking at how CollPlant Biotechnologies Ltd. brings in cash as of late 2025. It's a mix of upfront payments from big partners and product sales, which is typical for a company at this stage in the regenerative space. Honestly, the milestone payments are the headline drivers right now.

The most concrete revenue source recently came from the strategic collaboration with AbbVie. Following a key development milestone, CollPlant Biotechnologies received a $2 million milestone payment from AbbVie in February 2025, which was recorded in the first quarter of 2025 results. This payment relates to the development and commercialization agreement for dermal and soft tissue filler products using CollPlant's recombinant human collagen (rhCollagen) technology. That single event significantly boosted the top line early in the year.

Here's a quick look at how the revenue built up through the first nine months of 2025:

Period Ended	GAAP Revenue	Key Driver Mentioned
Q1 2025	$2.1 million	$2 million AbbVie milestone payment
Q3 2025	$77,000	Increase in sales of rhCollagen-based products
Nine Months Ended September 30, 2025	$2.3 million	Development milestone from AbbVie agreement

The nine-month 2025 GAAP revenue totaled $2.3 million, definitely a key metric for tracking progress against the prior year's nine-month revenue of $351,000 for the period ended September 30, 2024. That jump shows the impact of the AbbVie payment, but the smaller Q3 revenue suggests product sales are still ramping up.

Beyond the big partnership payments, CollPlant Biotechnologies Ltd. generates revenue from direct sales of its proprietary products. You need to track these streams as they represent the commercial viability of their platform technology:

• Sales of rhCollagen-based products, including the tendon-repair product, Vergenix™ STR. The company is actively expanding the international distribution network for Vergenix™ STR into new markets, including Europe and Asia.
• Sales of Collink.3D™ BioInk for research and bioprinting applications. CollPlant Biotechnologies announced the expansion of its BioInk sales in North America through a new logistics partnership and commercial leadership, aiming to enhance market presence. This bioink is used for things like creating tissue or organ-on-a-chip systems.

Licensing fees and royalties from commercial partners are an expected future stream, though current reports focus on expenses related to royalties. For instance, GAAP cost of revenues for the nine months ended September 30, 2025, included an increase in royalty expenses to the Israel Innovation Authority, mainly related to the $2 million milestone payment received from AbbVie in 2025. This shows that royalty obligations are tied to these upfront payments, with future commercial royalties yet to materialize significantly.

If onboarding takes 14+ days, churn risk rises, but for CollPlant Biotechnologies Ltd., the near-term focus is on converting the success of their bioink in comparative studies-like the one showing Collink.3D™ outperformed Matrigel® in structured tissue formation-into broader research sales. Finance: draft 13-week cash view by Friday.